Replies to post #109740 on Biotech Values

[zipjet]

It also will raise the chances that in the event TEVA gets approval and launches at-risk of an award of treble damages (should no PI issue).

ij

[DewDiligence]

…in the event of b), would MNTA go to a royalty position even though there is in fact no third product actually on the market due to pending legal action?

No—MNTA’s profit-share arrangement does not change to a royalty unless a competing generic Lovenox has actual commercial sales.